← Back to Home

Solrikitug Meets Both Primary Endpoints in Phase 2 Esophagitis Trial, Improving Swallowing Symptoms and Tissue Inflammation

Uniquity reports preliminary 24-week results for its anti-TSLP antibody, offering a new treatment lead for eosinophilic esophagitis; follow-up and Phase 3 trials will test whether efficacy persists and safety remains consistent.

By SURL BioNews

For patients with eosinophilic esophagitis, whether treatment makes eating easier is just as important as whether it reduces inflammation in esophageal tissue. Uniquity Bio announced on November 17 that all three tested doses of its antibody drug solrikitug met both co-primary endpoints in the Phase 2 ALAMERE trial, providing a basis for subsequent large-scale trials.

The randomized, double-blind, placebo-controlled study enrolled adult patients who received 125, 250, or 500 milligrams of solrikitug by subcutaneous injection every four weeks. The drug targets thymic stromal lymphopoietin (TSLP). Eosinophilic esophagitis is chronic inflammation of the esophagus associated with allergic immune responses that can cause difficulty swallowing and food impaction, and may lead to fibrosis and narrowing over time.

According to the 24-week results released by the company, placebo-adjusted histologic remission rates across the dose groups ranged from 69% to 76%, reaching statistical significance. This measure assesses the number of eosinophils in esophageal tissue. The announcement reported figures after subtracting the placebo effect; these cannot be interpreted directly as the actual proportion of patients in each treatment group who achieved remission.

For symptoms, Dysphagia Symptom Questionnaire (DSQ) scores fell by 8.8 to 12.6 points more than with placebo, reflecting improvements in the frequency and severity of difficulty swallowing. PharmaShots’ coverage of the same event on November 18 also summarized improvements in endoscopic scores, histologic disease activity, and days without dysphagia. However, that report cited the company’s announcement and was not a separate, independent clinical validation.

Efficacy signals at both the tissue and symptom levels help assess whether treatment addresses both inflammation control and patients’ everyday experience. However, the publicly available information remains a preliminary summary provided by the company and does not include the number of participants, unadjusted remission rates for each group, the remission threshold, or complete adverse event data. The company described tolerability as good, but this is not yet sufficient to fully assess safety or determine superiority over other therapies.

Uniquity is continuing to follow participants through 52 weeks to assess whether responses are maintained and evaluate longer-term safety, and expects to present the full results at a future medical meeting. The company also hopes to explore dosing intervals longer than four weeks. However, the efficacy reported in this announcement comes from dosing every four weeks, and whether longer intervals can maintain the effect remains to be verified.

Uniquity licensed solrikitug from Merck and plans to initiate a pivotal Phase 3 trial in the first quarter of 2027. The next priorities are to confirm whether these improvements can be reproduced in more comprehensive studies and clarify dosing, duration of efficacy, and safety, gradually translating these preliminary findings into evidence that can be evaluated clinically.

References

  1. Uniquity Bio
  2. PharmaShots